Are you Dr. Porteus?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 44 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Blvd
Dallas, TX 75390Phone+1 214-730-5437- Is this information wrong?
Summary
- Dr. Matthew Porteus, MD is a pediatric hematologist/oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas and California. He is affiliated with Lucile Packard Children's Hospital Stanford and Stanford Health Care.
Education & Training
- Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1996 - 1999
- Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1994 - 1996
- Stanford University School of MedicineClass of 1994
Certifications & Licensure
- CA State Medical License 2000 - 2023
- TX State Medical License 2003 - 2011
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
- Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
- Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
- Join now to see all
Publications & Presentations
PubMed
- Gene regulation in inborn errors of immunity: Implications for gene therapy design and efficacy.Hana Y Ghanim, Matthew H Porteus> ;Immunological Reviews. 2024 Mar 1
- 2 citationsReengineering Ponatinib to Minimize Cardiovascular Toxicity.Anna P Hnatiuk, Arne A N Bruyneel, Dhanir Tailor, Mallesh Pandrala, Arpit Dheeraj, Wenqi Li, Ricardo Serrano, Dries A M Feyen, Michelle M Vu, Prashila Amatya, Saloni G...> ;Cancer Research. 2022 Aug 3
- 4 citationsA Curative DNA Code for Hematopoietic Defects: Novel Cell Therapies for Monogenic Diseases of the Blood and Immune System.Matthew H Porteus, Mara Pavel-Dinu, Sung-Yun Pai> ;Hematology/oncology Clinics of North America. 2022 Aug 1
- Join now to see all
Press Mentions
- Hit Pause: The Read-Across to Graphite Bio’s CEDAR Sickle Cell Trial SuspensionJanuary 26th, 2023
- Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell DiseaseAugust 11th, 2022
- Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and ExpositionDecember 11th, 2021
- Join now to see all
Grant Support
- Using Zinc Finger Nucleases To Stimulate Gene Targeting In HSCNational Heart, Lung, And Blood Institute2006–2009
- Zinc Finger Nucleases To Stimulate Gene Targeting In Hematopoietic Stem CellsNational Heart, Lung, And Blood Institute2007
- Development Of Gene Targeting In C. Elegans And D. Rerio Using Zinc FingerNational Cancer Institute2006–2007
- The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2003–2006
- The Genetics Of Gene Targeting In Vertebrate CellsNational Heart, Lung, And Blood Institute2002
Hospital Affiliations
- Lucile Packard Children's Hospital StanfordPalo Alto, California
- Stanford Health CarePalo Alto, California